NVO241122P102000
- 0.03
- -0.60-95.24%
Novo-Nordisk A/S Newsroom
Are Hedge Funds Betting Big on Novo Nordisk (NVO)'s Diabetes and Chronic Disease Care?
The EU may unconditionally approve novo-nordisk a/s's acquisition of catalent.
The European Commission may unconditionally approve novo-nordisk a/s's parent company, Novo Holdings, to acquire the usa contract pharmaceutical company catalent for 16.5 billion USD.
The Trader: Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barron's
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $156
Smart Money Is Betting Big In NVO Options
Unusual Options Activity: LRCX, COIN and Others Attract Market Bets, LRCX V/OI Ratio Reaches 119.0
EU Antitrust Regulators Expected to Approve Novo Holdings' $16.5B Acquisition of Catalent Without Conditions
Viking Therapeutics a New Buy at B Riley on Lead Obesity Asset VK2735
novo-nordisk a/s (NVO.US) has signed a contract with Ypsomed to produce the next generation of injection pens for weight loss medication.
novo-nordisk a/s has announced that it has signed a contract with Ypsomed to produce the next generation of weight loss pen.
Novo Nordisk Said to Have Contracted Ypsomed to Make Next Gen Obesity Drug's Pens
Amgen (AMGN.US) weight loss drug is poised to launch, and Wall Street is eagerly awaiting the research results.
Amgen (AMGN.US) will soon release mid-term study data for the experimental weight loss drug MariTide, revealing a comparison of this drug with GLP-1 drugs from Eli Lilly (LLY.US) and novo-nordisk A/S (NVO.US).
In 2025, the global medical care industry is expected to usher in an investment boom, with a focus on Biotech.
Jefferies financial indicated that investor sentiment in the global medical care industry has significantly warmed up.
Optimism Over Global Healthcare Sector Rises: Jefferies
Eli Lilly Stock Tumbles As Kennedy Targets Weight Loss Drugs
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop -- Barrons.com
Novo-nordisk a/s stock price returns to the starting point of the year! Sales of weight loss medication fall short of expectations, scaring off investors.
①Danish pharmaceutical company novo-nordisk a/s saw its stock price drop by over 40% from the year's high due to intensified competition in the weight loss drug market, supply restrictions, and financial reports falling below expectations; ② Novo Nordisk's CFO admitted that next year's sales growth rate may be in the tens of percent, significantly lagging behind market expectations; ③ Analysts believe that the current excessive selling sentiment towards weight loss drugs, the company still has high investment value.
Novo Semaglutide Data in MASH Could Negatively Impact Madrigal's Rezdiffra
More Companies Covering Weight Loss Drugs for Their Employees